CLINICAL TRIAL: CHRONIC LYMPHOCYTIC LEUKEMIA

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 慢性淋巴细胞白血病是一种罕见的根治性疾病。需要新的治疗方法。像许多其他恶性肿瘤一样，在慢性淋巴细胞白血病中，肿瘤抑制基因可能会因DNA甲基化而沉默。Vidaza是一种DNA甲基化抑制剂，已经被批准用于治疗骨髓增生异常综合征患者。这项研究建议研究Vidaza是否是慢性淋巴细胞白血病患者的有效DNA甲基化抑制剂。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Chronic lymphocytic leukemia is rarely curative disease. Novel treatments are needed. Like many other malignancies, tumor suppressor genes may be silenced by DNA methylation in chronic lymphocytic leukemia. Vidaza, a DNA methylation inhibitor, is already approved for treatment of patients with myelodysplastic syndrome. This study proposes to study if Vidaza is an effective DNA methylation inhibitor in patients with chronic lymphocytic leukemia.